N-[2-hydroxy-6-(hydroxymethyl)-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-3-yl]acetamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[2-hydroxy-6-(hydroxymethyl)-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-3-yl]acetamide
• 化学式: C₂₀H₃₅NO₁₅
• 分子量: 529.5
• InChiKey: CFDVGUXRLQWLJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.8
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  257
• 氢给体数：
  10
• 氢受体数：
  15

文献信息

• Compositions and methods for treatment of inflammatory disorders
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US10668092B2

  公开（公告）日：2020-06-02

  The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.

  本发明涉及通过施用新发现的具有 TLR4 抑制活性的各种化合物来治疗感染性、炎症性和创伤后疾病的方法。除治疗方法外，本发明还进一步提供了药物组合物，其中包含上述化合物以及合适的药物载体。
• ANTAGONISTE SPÉCIFIQUE DE TLR4 DANS LE TRAITEMENT DU MYÉLOME MULTIPLE
  申请人：Etablissement Français du Sang

  公开号：EP3558323A1

  公开（公告）日：2019-10-30
• COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20180280418A1

  公开（公告）日：2018-10-04

  The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.
• SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA
  申请人：Etablissement Français du Sang

  公开号：US20220023325A1

  公开（公告）日：2022-01-27

  The present invention relates to a TLR4 (toll-like receptor 4) specific antagonist for use in the treatment of multiple myeloma in a subject suffering from multiple myeloma, and also to an antitumor pharmaceutical combination comprising (i) a TLR4-specific antagonist and (ii) a chemotherapy agent for simultaneous, separate or sequential use in the treatment of multiple myeloma.